Ability of the VITEK 2 Advanced Expert System To Identify β-Lactam Phenotypes in Isolates of Enterobacteriaceae and Pseudomonas aeruginosa
Open Access
- 1 February 2000
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 38 (2) , 570-574
- https://doi.org/10.1128/jcm.38.2.570-574.2000
Abstract
The Advanced Expert System (AES) was used in conjunction with the VITEK 2 automated antimicrobial susceptibility test system to ascertain the β-lactam phenotypes of 196 isolates of the family Enterobacteriaceae and the species Pseudomonas aeruginosa . These isolates represented a panel of strains that had been collected from laboratories worldwide and whose β-lactam phenotypes had been characterized by biochemical and molecular techniques. The antimicrobial susceptibility of each isolate was determined with the VITEK 2 instrument, and the results were analyzed with the AES to ascertain the β-lactam phenotype. The results were then compared to the β-lactam resistance mechanism determined by biochemical and molecular techniques. Overall, the AES was able to ascertain a β-lactam phenotype for 183 of the 196 (93.4%) isolates tested. For 111 of these 183 (60.7%) isolates, the correct β-lactam phenotype was identified definitively in a single choice by the AES, while for an additional 46 isolates (25.1%), the AES identified the correct β-lactam phenotype provisionally within two or more choices. For the remaining 26 isolates (14.2%), the β-lactam phenotype identified by the AES was incorrect. However, for a number of these isolates, the error was due to remediable problems. These results suggest that the AES is capable of accurate identification of the β-lactam phenotypes of gram-negative isolates and that certain modifications can improve its performance even further.Keywords
This publication has 16 references indexed in Scilit:
- Can Results Obtained with Commercially Available MicroScan Microdilution Panels Serve as an Indicator of β-Lactamase Production among Escherichia coli and Klebsiella Isolates with Hidden Resistance to ExpandedSpectrum Cephalosporins and Aztreonam?Journal of Clinical Microbiology, 1998
- Evolution and Dissemination of β-Lactamases Accelerated by Generations of β-Lactam AntibioticsClinical Infectious Diseases, 1997
- beta-Lactamases in laboratory and clinical resistanceClinical Microbiology Reviews, 1995
- A functional classification scheme for beta-lactamases and its correlation with molecular structureAntimicrobial Agents and Chemotherapy, 1995
- Development of test panel of beta-lactamases expressed in a common Escherichia coli host background for evaluation of new beta-lactam antibioticsAntimicrobial Agents and Chemotherapy, 1995
- -Lactam Resistance in Gram-Negative Bacteria: Global Trends and Clinical ImpactClinical Infectious Diseases, 1992
- -Lactamases of Gram-Negative Bacteria: New Challenges for New DrugsClinical Infectious Diseases, 1992
- A new plasmidic cefotaximase in a clinical isolate of Escherichia coliInfection, 1990
- Heterogeneity of class I beta-lactamase expression in clinical isolates of Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 1988
- The Use of Analytical Isoelectric Focusing for Detection and Identification of -LactamasesJournal of General Microbiology, 1975